Hypercoagulable States

The main question in most patient groups detailed below is whether they can expect a net benefit from pharmacological thromboprophylaxis, mainly low-molecular-weight heparins (LMWH). One has to balance the risk of venous thromboembolism (VTE) and the consequences of VTE with the risk of bleeding and other complications. Ideally, this balance is sought in every individual patient, also taking the values and preferences of that patient into consideration.

To facilitate this balancing process, institutions and national and international organizations have developed guidelines for the use of thromboprophylaxis. The use of these guidelines and local protocols has greatly improved patient outcomes, mainly by increasing the use of pharmacological thromboprophylaxis in patients at risk for VTE. We strongly advise the development and use of a local protocol.